Core Viewpoint - Rongchang Biologics has signed an exclusive licensing agreement with AbbVie for the dual-specific antibody drug RC148, valued at approximately $5.6 billion (about 39.06 billion RMB), marking a significant milestone in the company's business development efforts [1][3]. Group 1: Business Development Transactions - The agreement with AbbVie includes an upfront payment of $650 million (about 4.53 billion RMB) and potential milestone payments of up to $4.95 billion (about 34.53 billion RMB) based on development, regulatory, and commercialization achievements [3]. - This transaction is noted as the highest upfront payment recorded in the innovative drug sector for business development (BD) transactions at the start of the year [3]. - Since 2025, Rongchang Biologics has completed three BD transactions, including the recent agreement with AbbVie, indicating a strategic push for international expansion [5][6]. Group 2: Financial Performance - For the first three quarters of 2025, Rongchang Biologics reported revenue of approximately 1.72 billion RMB, a year-on-year increase of 42.27%, while the net loss narrowed to 551 million RMB [7]. - The company’s cash reserves reached 1.07 billion RMB by the end of Q3 2025, an increase from 743 million RMB and 763 million RMB at the end of 2023 and 2024, respectively [7]. - Despite the increase in cash reserves, the company still faces a high debt ratio of 61.18% as of Q3 2025, indicating ongoing financial pressure [7]. Group 3: Market Reaction - On January 13, following the announcement of the AbbVie deal, Rongchang Biologics' A-shares hit the daily limit, closing at a 20% increase, with a total trading volume of 2.369 billion RMB [2]. - The H-shares also experienced a significant rise, closing up 7.87% [2]. - The market's positive response reflects investor confidence in the potential of the RC148 drug and the strategic partnership with AbbVie [6][8].

| 买入营业部名称 | 买入金额(万元) | | --- | --- | | 机构专用 | 17466.68 | | 沪股通专用 | 7867.82 | | 国泰海通证券股份有限公司上海长宁区江苏路证券营业部 | 6592.05 | | 国泰海通证券股份有限公司上海分公司 | 4578.39 | | 中国银河证券股份有限公司三亚迎宾路证券营业部 | 4115.26 | | 卖出营业部名称 | 卖出金额(万元) | | 沪股通专用 | 14554.86 | | 长城证券股份有限公司北京西直门外大街证券营业部 | 8537.77 | | 中国中金财富证券有限公司北京北三环东路证券营业部 | 8334.90 | | 机构专用 | 5296.79 | | 机构专用 | 4466.19 | （文章来源：证券时报网） 资金流向方面，该股今日全天主力资金净流出1675.99万元。（数据宝） 荣昌生物1月13日龙虎榜 1月13日荣昌生物（688331）收盘价114.46元，收盘涨停，全天换手率13.08%，振幅10.06%，成交额 23.69亿元。科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。 证券时报·数据 ...

Market Overview - On January 13, the Hang Seng Index rose by 0.90%, with total southbound trading amounting to HKD 137.35 billion, including buy transactions of HKD 69.32 billion and sell transactions of HKD 68.03 billion, resulting in a net buying amount of HKD 1.30 billion [1] Southbound Trading Activity - The southbound trading through Stock Connect (Shenzhen) recorded a total trading amount of HKD 54.86 billion, with buy transactions of HKD 28.00 billion and sell transactions of HKD 26.85 billion, leading to a net buying amount of HKD 1.15 billion [1] - The southbound trading through Stock Connect (Shanghai) had a total trading amount of HKD 82.49 billion, with buy transactions of HKD 41.32 billion and sell transactions of HKD 41.17 billion, resulting in a net buying amount of HKD 0.15 billion [1] Active Stocks - Alibaba-W was the most actively traded stock with a total trading amount of HKD 139.06 billion and a net buying amount of HKD 10.71 billion, closing with a price increase of 3.63% [1][2] - Tencent Holdings followed with a total trading amount of HKD 52.93 billion and a net buying amount of HKD 7.56 billion, closing with a price increase of 0.72% [1][2] - Xiaomi Group-W had a total trading amount of HKD 49.62 billion and a net buying amount of HKD 6.07 billion, closing with a price decrease of 1.96% [1][2] Continuous Net Buying and Selling - Three stocks experienced continuous net buying for more than three days, with Xiaomi Group-W, Tencent Holdings, and Kuaishou-W having net buying days of 9, 5, and 3 respectively [2] - Tencent Holdings had the highest cumulative net buying amount of HKD 69.99 billion, followed closely by Xiaomi Group-W with HKD 69.33 billion [2] - Two stocks faced continuous net selling, with China Mobile and Meituan-W having net selling amounts of HKD 52.84 billion and HKD 11.67 billion respectively [2]

Core Insights - The article highlights significant advancements in China's biopharmaceutical sector, particularly in the PD-1/VEGF dual antibody space, marked by major deals and regulatory submissions that indicate a shift from follower to leader status for Chinese companies in the global market [1][2][3]. Group 1: Major Developments - Rongchang Biopharma announced a $5.6 billion licensing agreement with AbbVie for its PD-1/VEGF dual antibody RC148, with an upfront payment of $650 million and potential milestone payments of up to $4.95 billion [2]. - Summit Therapeutics, a partner of Kangfang Biopharma, submitted a Biologics License Application (BLA) for Ivoris monoclonal antibody to the FDA, targeting EGFR-mutant non-small cell lung cancer, with a decision expected in Q4 2026 [3]. Group 2: Market Dynamics - The PD-1/VEGF dual antibody market is becoming increasingly competitive, with major pharmaceutical companies investing heavily, indicating the high commercial value of this therapeutic area [5][6]. - The termination of a collaboration between Yiming Biotech and Instil Bio serves as a cautionary tale, highlighting challenges faced by Chinese innovative drug companies in global markets, including the need for strong financial backing and execution capabilities [1][7]. Group 3: Future Outlook - The success of Kangfang's Ivoris monoclonal antibody in clinical trials could position it as a leading product in the market, potentially capturing significant market share if it demonstrates strong overall survival data [4][10]. - The increasing number of PD-1/VEGF products in clinical stages, with 14 products linked to Chinese companies, suggests a crowded competitive landscape, which may complicate future business development opportunities for companies like Yiming Biotech [8][9].

Core Viewpoint - Rongchang Biologics has signed a significant exclusive licensing agreement with AbbVie for the dual-specific antibody drug RC148, with an upfront payment of $650 million and potential milestone payments up to $4.95 billion, totaling approximately $5.6 billion. This deal has led to a substantial increase in the company's stock prices, with A-shares hitting the daily limit and H-shares also experiencing significant gains [1][3][4]. Financial Impact - On January 13, Rongchang Biologics' A-shares opened 15.33% higher and closed at the daily limit of 114.46 yuan per share, marking a 20% increase and a total market capitalization of 645.2 billion yuan. The trading volume reached 2.369 billion yuan with a turnover rate of 13.08% [3]. - The H-shares also saw a rise, closing at 100.1 HKD per share, up 7.87% [4]. - The $650 million upfront payment from AbbVie is expected to alleviate the company's short-term cash flow issues, which have been a concern due to a high debt ratio of 61.18% and cash reserves of 1.07 billion yuan as of Q3 2025 [10][13]. Business Development Transactions - Since 2025, Rongchang Biologics has completed three major business development (BD) transactions, including the recent agreement with AbbVie. Previous deals included licensing agreements with Vor Bio and Santen Pharmaceutical, which also involved significant upfront and milestone payments [8][9]. - The RC148 drug targets PD-1 and VEGF pathways, aiming to enhance anti-tumor immune responses while inhibiting tumor-driven angiogenesis. Clinical studies are ongoing in China for various advanced malignancies [6][9]. Market Position and Future Outlook - The dual-target PD-1/VEGF antibody has become a popular target among multinational pharmaceutical companies, indicating a competitive landscape for such innovative therapies [7]. - The company aims to balance external licensing ("authorized blood transfusion") with internal development ("self-blood production") to ensure sustainable growth and enhance long-term value [14][15].

Core Insights - On January 13, 2026, Alibaba-W (09988), Tencent Holdings (00700), and Xiaomi Group-W (01810) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 81.05 billion, 29.45 billion, and 28.57 billion respectively [1] - The same companies also led in trading volume in the Shenzhen-Hong Kong Stock Connect, with trading amounts of 58.01 billion, 23.48 billion, and 21.05 billion respectively [1] Southbound Stock Connect (Shanghai-Hong Kong) - Alibaba-W (09988) had a trading amount of 81.05 billion and a net buy amount of -90.46 million [2] - Tencent Holdings (00700) recorded a trading amount of 29.45 billion with a net buy amount of +6.61 million [2] - Xiaomi Group-W (01810) achieved a trading amount of 28.57 billion and a net buy amount of +3.24 billion [2] - Other notable companies included Goldwind Technology (02208) with 23.07 billion and a net buy of +85.70 million, and SMIC (00981) with 22.72 billion and a net buy of -1.73 billion [2] Southbound Stock Connect (Shenzhen-Hong Kong) - Alibaba-W (09988) had a trading amount of 58.01 billion and a net buy amount of +1.16 billion [2] - Tencent Holdings (00700) recorded a trading amount of 23.48 billion with a net buy amount of +749 million [2] - Xiaomi Group-W (01810) achieved a trading amount of 21.05 billion and a net buy amount of +283 million [2] - Other significant companies included SMIC (00981) with 18.13 billion and a net buy of -661 million, and Kuaishou-W (01024) with 12.21 billion and a net buy of +114 million [2]

Market Overview - A-shares opened high but closed lower, with the Shanghai Composite Index down 0.64%, Shenzhen Component Index down 1.37%, and ChiNext Index down 1.96%. The total trading volume in the Shanghai and Shenzhen markets was approximately 3.70 trillion yuan, showing a slight increase compared to the previous trading day. More than 3,700 stocks declined [1] Industry Insights - The commercial aerospace sector saw significant activity, leading to a market pullback. However, this correction is considered normal after continuous gains, and the spring market trend is expected to continue. Investors are advised to focus on technology growth and related sectors such as commercial aerospace, AI applications, and new energy, while also considering cash flow/dividend assets to mitigate market volatility [1] - The medical services, precious metals, and GEO concept stocks were among the top gainers today, while commercial aerospace, semiconductors, and chemical fiber industries experienced the largest declines [1] Pharmaceutical Sector Highlights - The pharmaceutical sector led the market gains due to several key developments: 1. Rongchang Bio signed an exclusive licensing agreement with AbbVie for RC148, with a total transaction value of 5.6 billion USD, highlighting the significant market potential of the PD-1/VEGF dual antibody track [2] 2. WuXi AppTec, a leading CXO, announced its 2025 performance forecast, expecting annual revenue of 45.456 billion yuan, a year-on-year increase of 15.84%, exceeding expectations [2] 3. Tempus AI reported better-than-expected earnings, with diagnostic business revenue of 955 million USD, a year-on-year growth of 111%, indicating ongoing global advancements in AI medical technology [2] - The pharmaceutical sector's global competitiveness continues to strengthen, with ongoing international expansion and commercial profitability [2] Power Grid Sector Developments - The domestic power grid performed relatively well in the afternoon, driven by the demand for renewable energy consumption from large-scale wind and solar projects. The vast territory of China necessitates long-distance transportation, which is expected to further stimulate demand for UHV (Ultra High Voltage) construction. During the 14th Five-Year Plan period, UHV DC is expected to maintain an annual approval pace of 3 to 4 lines, while UHV AC is anticipated to approve an average of 2 large projects annually [2] - In North America, explosive growth in AIDC (Artificial Intelligence Data Center) is creating new electricity demand, and China's complete power grid industry chain, efficient delivery, and rich overseas experience position it as a key supplier to fill this gap [2]

Market Performance - The Hong Kong stock market saw a significant early rise but narrowed gains in the afternoon, with the Hang Seng Index closing at 26,848.47 points, up 239.99 points, or 0.90% [1] - The total trading volume for the day was 315.2 billion HKD, showing a slight increase compared to the previous day [1] Sector Highlights - Gold stocks continued their upward trend, with China Gold International (HK02099) rising over 7%, Lingbao Gold (HK03330) up nearly 3%, and Zijin Mining (HK01818) and Shandong Gold (HK01787) both increasing over 2% [3] - The Hang Seng Tech Index closed at 5,869.79 points, up 6.59 points, or 0.11% [4] Company News - Citigroup has aggressively raised its short-term outlook for precious metals, predicting gold prices could reach 5,000 USD/oz and silver 100 USD/oz within three months due to escalating geopolitical risks, physical shortages, and uncertainties in Federal Reserve policies [6] - Innovative drug concept stocks performed well, with WuXi AppTec (HK02359) rising over 8% [7] - WuXi AppTec announced an expected annual revenue of 45.456 billion CNY, a year-on-year increase of 15.84%, with adjusted net profit expected to rise by approximately 41.33% to 14.957 billion CNY [9] - Rongchang Biopharmaceutical (HK09995) signed an exclusive licensing agreement with AbbVie for its new dual-target PD-1/VEGF antibody drug RC148, receiving an upfront payment of 650 million USD and potential total payments of up to 5.6 billion USD [11] Market Outlook - Guosen Securities noted that the Hong Kong stock market has not yet fully strengthened, with traditional industries still dominating, and concerns over intensified competition among internet companies affecting market sentiment [13] - The pricing power of Hong Kong stocks is influenced by overseas risk appetite, and the appreciation of the RMB is being offset by profit-taking sentiment [13] - The AH premium index indicates that quality H-shares are preferred over A-shares, with domestic investors favoring leading companies through southbound channels [13]

格隆汇1月13日｜中信建投证券研报指出，荣昌生物与艾伯维就RC148（PD1/VEGF）实现全球合作，整 体交易的首付款为6.5亿美元，并有资格获得最高达49.5亿美元的开发、监管和商业化里程碑付款，同时 还拥有在大中华地区以外的净销售额的两位数分级特许权使用费，首付款和总金额超出市场预期。具体 来看，RC148此前在1L NSCLC和后线NSCLC中均展现出优异临床数据，药物目前在多个实体瘤中开展 临床研究，未来可期。认为本次合作让公司的国际化得到进一步加强，看好公司未来发展。预计2025- 2027年，公司收入分别为24.55亿元、33.88亿元和45.74亿元，维持"买入"评级。（暂不考虑BD的收入 确认影响） ...

Group 1 - The core point of the news is the significant licensing agreement between Rongchang Biopharma and AbbVie for the development and commercialization of RC148, a novel bispecific antibody targeting PD-1 and VEGF, which could lead to substantial financial benefits for Rongchang Biopharma [1] - Rongchang Biopharma will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in milestone payments, along with double-digit royalties on net sales outside Greater China [1] - The deal exemplifies the "China innovation + global market" model in drug development, indicating a growing trend of collaboration between Chinese biotech firms and international pharmaceutical companies [1] Group 2 - In 2024, U.S. pharmaceutical companies significantly increased their acquisition of Chinese innovative drugs, with a year-on-year growth of 66%, leading to a total licensing transaction value of $41.5 billion [2] - Recently, five business development projects have been established in a short period, covering various fields such as small molecule inhibitors, monoclonal antibodies, bispecific antibodies, ADCs, and RDCs, indicating a flourishing environment for Chinese innovative drugs [2] - The Hong Kong innovation drug sector is showing signs of recovery, with the Hang Seng Innovation Drug Index having corrected approximately 25% since its peak in September 2025, but is now rebounding [3] Group 3 - The U.S. biotech sector, particularly the Nasdaq Biotechnology Index, has reached new highs, increasing by 23% since September of last year, highlighting a disparity in performance compared to the Hong Kong innovation drug sector [5] - The recent surge in business development projects serves as a catalyst that may reactivate the Hong Kong innovation drug sector, which is currently perceived to be at a relatively safe valuation compared to the Nasdaq [5]